<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05118334</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI310H201</org_study_id>
    <nct_id>NCT05118334</nct_id>
  </id_info>
  <brief_title>IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer(NSCLC)</brief_title>
  <official_title>An Open Label, Multicenter, Phase Ib Study Evaluating IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Advanced, Recurrent or Metastatic Non-small-cell Lung Cancer(NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, multicenter, phase Ib study evaluating IBI310 (anti-CTLA-4) in&#xD;
      combination with Sintilimab in patients with advanced, recurrent or metastatic non-small-cell&#xD;
      lung cancer(NSCLC)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 12, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Investigator evaluated ORR per RECIST V1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Emergent Adverse Event (TEAE)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Incidence and severity of treatment-emergent: which is evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, v5.0) grade;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe Adverse Event (SAE)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Incidence and severity of treatment-emergent: which is evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, v5.0) grade;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the time from the first documented objective response to the first documented progressive disease or death of any cause, whichever occurs first;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the time from randomization to the first documented progressive disease or death of any cause, whichever occurs first;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the time from randomization to death of any cause in subjects without receiving any immunotherapy outside the study protocol for first-line treatment of advanced NSCLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the proportion of patients whose best response is CR, PR, and stable disease (SD) non-CR/non-PD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the time from randomization to the first documented and confirmed objective response (CR or PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRQoL</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>According to EORTC QLQ-C30</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>NSCLC (Non-small-cell Lung Cancer)</condition>
  <arm_group>
    <arm_group_label>IBI310 (anti-CTLA-4) 1mg/kg(Q3W until progressive disease)in combination with Sintilimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The test group will be treated with IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI310 (anti-CTLA-4) 1mg/kg(Q3W*4cycles)in combination with Sintilimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The test group will be treated with IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W*4cycles,and then Sintilimab 200 mg IV, Q3W single until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI310 (anti-CTLA-4) 1mg/kg(Q6W)in combination with Sintilimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The test group will be treated with IBI310 1mg/kg IV, Q6W+ Sintilimab 200 mg IV, Q3Wuntil progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI310 (anti-CTLA-4) 0.5mg/kg in combination with Sintilimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The test group will be treated with IBI310 0.5mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>(IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W)until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.</description>
    <arm_group_label>IBI310 (anti-CTLA-4) 0.5mg/kg in combination with Sintilimab</arm_group_label>
    <arm_group_label>IBI310 (anti-CTLA-4) 1mg/kg(Q3W until progressive disease)in combination with Sintilimab</arm_group_label>
    <arm_group_label>IBI310 (anti-CTLA-4) 1mg/kg(Q3W*4cycles)in combination with Sintilimab</arm_group_label>
    <arm_group_label>IBI310 (anti-CTLA-4) 1mg/kg(Q6W)in combination with Sintilimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI310</intervention_name>
    <description>(IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W) until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.</description>
    <arm_group_label>IBI310 (anti-CTLA-4) 0.5mg/kg in combination with Sintilimab</arm_group_label>
    <arm_group_label>IBI310 (anti-CTLA-4) 1mg/kg(Q3W until progressive disease)in combination with Sintilimab</arm_group_label>
    <arm_group_label>IBI310 (anti-CTLA-4) 1mg/kg(Q3W*4cycles)in combination with Sintilimab</arm_group_label>
    <arm_group_label>IBI310 (anti-CTLA-4) 1mg/kg(Q6W)in combination with Sintilimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Criteria:&#xD;
&#xD;
          1. Aged ≥18 years;&#xD;
&#xD;
          2. ECOG 0 ~ 1;&#xD;
&#xD;
          3. Histologically /cytologically confirmed R/M NSCLC;&#xD;
&#xD;
          4. Adequate organ and bone marrow function;&#xD;
&#xD;
          5. Expected survival ≥12 weeks;&#xD;
&#xD;
          6. Female subjects of childbearing age or male patients whose sex partners are women of&#xD;
             childbearing age should take effective contraceptive measures throughout the treatment&#xD;
             period and within 6 months after the last administration;&#xD;
&#xD;
          7. Subjects who sign the written informed consent form, and can abide by the visits and&#xD;
             related procedures specified in the protocol.&#xD;
&#xD;
          8. At least 1 measurable lesion according to the Response Evaluation Criteria in Solid&#xD;
             Tumors Version 1.1(RECIST V1.1).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Had tumors other than NSCLC within the past 5 years.&#xD;
&#xD;
          2. Had allogeneic organ or stem cell transplantation.&#xD;
&#xD;
          3. The presence of uncontrolled life-threatening illness&#xD;
&#xD;
          4. Women of child-bearing potential who are pregnant or breastfeeding because of the&#xD;
             potentially dangerous effects of the preparative chemotherapy on the fetus or infant.&#xD;
&#xD;
          5. Patients who have used large doses of glucocorticoids, anti-cancer monoclonal&#xD;
             antibodies, and other immunosuppressive agents within 4 weeks.&#xD;
&#xD;
          6. HIV positive.&#xD;
&#xD;
          7. Patients with significantly lower heart, liver, lung, kidney and bone marrow function.&#xD;
&#xD;
          8. Severe, uncontrolled medical conditions and infections.&#xD;
&#xD;
          9. At the same time using other test drugs or in other clinical trials.&#xD;
&#xD;
         10. Refusal or inability to sign informed consent to participate in the trial.&#xD;
&#xD;
         11. Other treatment contraindications.&#xD;
&#xD;
         12. Emotional disturbance or mental illness, no civil capacity or limited capacity for&#xD;
             civil conduct.&#xD;
&#xD;
         13. Hepatitis B surface antigen (HBsAg) positive and HBVDNA ≥1000cps/ml.&#xD;
&#xD;
         14. Patients with positive HCV antibody test results can only be included in the study&#xD;
             when the polymerase chain reaction of HCV RNA is negative.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiuzhi Yu</last_name>
    <phone>0512-69566088</phone>
    <email>xiuzhi.yu@innoventbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiuwei Cui</last_name>
    <phone>0431- 85612740</phone>
    <email>jdyycjw@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jiuwei Cui, Doctor</last_name>
      <phone>0431- 85612740</phone>
      <email>jdyycjw@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 1, 2021</study_first_submitted>
  <study_first_submitted_qc>November 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

